Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Tumor necrosis factor receptor family costimulation increases regulatory T-cell activation and function via NF-κB.

Lubrano di Ricco M, Ronin E, Collares D, Divoux J, Grégoire S, Wajant H, Gomes T, Grinberg-Bleyer Y, Baud V, Marodon G, Salomon BL.

Eur J Immunol. 2020 Feb 3. doi: 10.1002/eji.201948393. [Epub ahead of print]

PMID:
32012260
2.

Correction: TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP.

Knop J, Spilgies LM, Rufli S, Reinhart R, Vasilikos L, Yabal M, Owsley E, Jost PJ, Marsh RA, Wajant H, Robinson MD, Kaufmann T, Wong WW.

Cell Death Dis. 2020 Jan 23;11(1):56. doi: 10.1038/s41419-020-2261-2.

3.

Single-molecule imaging reveals the oligomeric state of functional TNFα-induced plasma membrane TNFR1 clusters in cells.

Karathanasis C, Medler J, Fricke F, Smith S, Malkusch S, Widera D, Fulda S, Wajant H, van Wijk SJL, Dikic I, Heilemann M.

Sci Signal. 2020 Jan 14;13(614). pii: eaax5647. doi: 10.1126/scisignal.aax5647.

PMID:
31937565
4.

Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.

Munawar U, Roth M, Barrio S, Wajant H, Siegmund D, Bargou RC, Kortüm KM, Stühmer T.

Sci Rep. 2019 Dec 2;9(1):18062. doi: 10.1038/s41598-019-54407-4.

5.

On-target restoration of a split T cell-engaging antibody for precision immunotherapy.

Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, Krenz B, Lutz J, Rasche L, Hönemann D, Neuweiler H, Heiby JC, Bargou RC, Wajant H, Einsele H, Riethmüller G, Stuhler G.

Nat Commun. 2019 Nov 26;10(1):5387. doi: 10.1038/s41467-019-13196-0.

6.

A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.

Fayez S, Li J, Feineis D, Aké Assi L, Kaiser M, Brun R, Anany MA, Wajant H, Bringmann G.

J Nat Prod. 2019 Nov 22;82(11):3033-3046. doi: 10.1021/acs.jnatprod.9b00589. Epub 2019 Oct 23.

PMID:
31642313
7.

Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer.

Wajant H, Beilhack A.

Front Immunol. 2019 Aug 28;10:2040. doi: 10.3389/fimmu.2019.02040. eCollection 2019. Review.

8.

TRAF2 Controls Death Receptor-Induced Caspase-8 Processing and Facilitates Proinflammatory Signaling.

Kreckel J, Anany MA, Siegmund D, Wajant H.

Front Immunol. 2019 Aug 29;10:2024. doi: 10.3389/fimmu.2019.02024. eCollection 2019.

9.

TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP.

Knop J, Spilgies LM, Rufli S, Reinhart R, Vasilikos L, Yabal M, Owsley E, Jost PJ, Marsh RA, Wajant H, Robinson MD, Kaufmann T, Wong WW.

Cell Death Dis. 2019 Sep 20;10(10):700. doi: 10.1038/s41419-019-1938-x. Erratum in: Cell Death Dis. 2020 Jan 23;11(1):56.

10.

The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death.

El-Mesery M, Rosenthal T, Rauert-Wunderlich H, Schreder M, Stühmer T, Leich E, Schlosser A, Ehrenschwender M, Wajant H, Siegmund D.

Cell Death Dis. 2019 Aug 13;10(8):611. doi: 10.1038/s41419-019-1860-2.

11.

Bioactive Brominated Oxindole Alkaloids from the Red Sea Sponge Callyspongia siphonella.

El-Hawary SS, Sayed AM, Mohammed R, Hassan HM, Rateb ME, Amin E, Mohammed TA, El-Mesery M, Bin Muhsinah A, Alsayari A, Wajant H, Anany MA, Abdelmohsen UR.

Mar Drugs. 2019 Aug 9;17(8). pii: E465. doi: 10.3390/md17080465.

12.

Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation.

Wajant H.

Cancers (Basel). 2019 Jul 7;11(7). pii: E954. doi: 10.3390/cancers11070954. Review.

13.

TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages.

Wajant H, Siegmund D.

Front Cell Dev Biol. 2019 May 29;7:91. doi: 10.3389/fcell.2019.00091. eCollection 2019. Review.

14.

Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target.

Medler J, Wajant H.

Expert Opin Ther Targets. 2019 Apr;23(4):295-307. doi: 10.1080/14728222.2019.1586886. Epub 2019 Mar 19.

PMID:
30856027
15.

TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity.

Medler J, Nelke J, Weisenberger D, Steinfatt T, Rothaug M, Berr S, Hünig T, Beilhack A, Wajant H.

Cell Death Dis. 2019 Mar 4;10(3):224. doi: 10.1038/s41419-019-1456-x.

16.

Redundant and receptor-specific activities of TRADD, RIPK1 and FADD in death receptor signaling.

Füllsack S, Rosenthal A, Wajant H, Siegmund D.

Cell Death Dis. 2019 Feb 11;10(2):122. doi: 10.1038/s41419-019-1396-5.

17.

Soluble TNF-like weak inducer of apoptosis (TWEAK) enhances poly(I:C)-induced RIPK1-mediated necroptosis.

Anany MA, Kreckel J, Füllsack S, Rosenthal A, Otto C, Siegmund D, Wajant H.

Cell Death Dis. 2018 Oct 22;9(11):1084. doi: 10.1038/s41419-018-1137-1.

18.

TNFR2 unlocks a RIPK1 kinase activity-dependent mode of proinflammatory TNFR1 signaling.

Siegmund D, Ehrenschwender M, Wajant H.

Cell Death Dis. 2018 Sep 11;9(9):921. doi: 10.1038/s41419-018-0973-3.

19.

New Cytotoxic Cyclic Peptide from the Marine Sponge-Associated Nocardiopsis sp. UR67.

Ibrahim AH, Attia EZ, Hajjar D, Anany MA, Desoukey SY, Fouad MA, Kamel MS, Wajant H, Gulder TAM, Abdelmohsen UR.

Mar Drugs. 2018 Aug 21;16(9). pii: E290. doi: 10.3390/md16090290.

20.

Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.

Cuchet-Lourenço D, Eletto D, Wu C, Plagnol V, Papapietro O, Curtis J, Ceron-Gutierrez L, Bacon CM, Hackett S, Alsaleem B, Maes M, Gaspar M, Alisaac A, Goss E, AlIdrissi E, Siegmund D, Wajant H, Kumararatne D, AlZahrani MS, Arkwright PD, Abinun M, Doffinger R, Nejentsev S.

Science. 2018 Aug 24;361(6404):810-813. doi: 10.1126/science.aar2641. Epub 2018 Jul 19.

21.
22.

Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.

Sirtl S, Knoll G, Trinh DT, Lang I, Siegmund D, Gross S, Schuler-Thurner B, Neubert P, Jantsch J, Wajant H, Ehrenschwender M.

Oncogene. 2018 Jul;37(30):4122-4136. doi: 10.1038/s41388-018-0265-5. Epub 2018 Apr 30.

23.

Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells.

Ticha O, Moos L, Wajant H, Bekeredjian-Ding I.

Front Immunol. 2018 Jan 19;8:1951. doi: 10.3389/fimmu.2017.01951. eCollection 2017.

24.

[Biofabrication: new approaches for tissue regeneration].

Horch RE, Weigand A, Wajant H, Groll J, Boccaccini AR, Arkudas A.

Handchir Mikrochir Plast Chir. 2018 Apr;50(2):93-100. doi: 10.1055/s-0043-124674. Epub 2018 Jan 29. Review. German.

PMID:
29378379
25.

Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice.

Lamontain V, Schmid T, Weber-Steffens D, Zeller D, Jenei-Lanzl Z, Wajant H, Straub RH, Männel DN.

Cell Mol Immunol. 2019 Jan;16(1):65-74. doi: 10.1038/cmi.2017.138. Epub 2018 Jan 29.

26.

Chronic Inflammation Increases the Sensitivity of Mouse Treg for TNFR2 Costimulation.

Schmid T, Falter L, Weber S, Müller N, Molitor K, Zeller D, Weber-Steffens D, Hehlgans T, Wajant H, Mostböck S, Männel DN.

Front Immunol. 2017 Nov 7;8:1471. doi: 10.3389/fimmu.2017.01471. eCollection 2017.

27.

The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent.

Lagler C, El-Mesery M, Kübler AC, Müller-Richter UDA, Stühmer T, Nickel J, Müller TD, Wajant H, Seher A.

PLoS One. 2017 Oct 13;12(10):e0185720. doi: 10.1371/journal.pone.0185720. eCollection 2017.

28.

TRAIL- and TNF-induced signaling complexes-so similar yet so different.

Wajant H.

EMBO J. 2017 May 2;36(9):1117-1119. doi: 10.15252/embj.201796997. Epub 2017 Apr 11. No abstract available.

29.

Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.

Kums J, Nelke J, Rüth B, Schäfer V, Siegmund D, Wajant H.

MAbs. 2017 Apr;9(3):506-520. doi: 10.1080/19420862.2016.1274844. Epub 2017 Jan 17.

30.

Generation and Application of Bioluminescent CD95 Ligand Fusion Proteins.

Lang I, Kums J, Wajant H.

Methods Mol Biol. 2017;1557:63-77. doi: 10.1007/978-1-4939-6780-3_7.

PMID:
28078583
31.

Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis.

Siegmund D, Kums J, Ehrenschwender M, Wajant H.

Cell Death Dis. 2016 Sep 22;7(9):e2375. doi: 10.1038/cddis.2016.285.

32.

Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.

Dagvadorj N, Deuretzbacher A, Weisenberger D, Baumeister E, Trebing J, Lang I, Köchel C, Kapp M, Kapp K, Beilhack A, Hünig T, Einsele H, Wajant H, Grigoleit GU.

Cancer Immunol Immunother. 2017 Mar;66(3):319-332. doi: 10.1007/s00262-016-1938-y. Epub 2016 Nov 28.

PMID:
27896368
33.

Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor-Mediated Destruction of Intestinal Epithelial Cells.

Grabinger T, Bode KJ, Demgenski J, Seitz C, Delgado ME, Kostadinova F, Reinhold C, Etemadi N, Wilhelm S, Schweinlin M, Hänggi K, Knop J, Hauck C, Walles H, Silke J, Wajant H, Nachbur U, W Wei-Lynn W, Brunner T.

Gastroenterology. 2017 Mar;152(4):867-879. doi: 10.1053/j.gastro.2016.11.019. Epub 2016 Nov 24.

34.

Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2.

Siegmund D, Lang I, Wajant H.

FEBS J. 2017 Apr;284(8):1131-1159. doi: 10.1111/febs.13968. Epub 2016 Dec 14. Review.

35.

Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.

Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, Vaeth M, Kuen J, Holtappels R, Podlech J, Mottok A, Kraus S, Jordán-Garrote AL, Bäuerlein CA, Brede C, Ribechini E, Fick A, Seher A, Polz J, Ottmüller KJ, Baker J, Nishikii H, Ritz M, Mattenheimer K, Schwinn S, Winter T, Schäfer V, Krappmann S, Einsele H, Müller TD, Reddehase MJ, Lutz MB, Männel DN, Berberich-Siebelt F, Wajant H, Beilhack A.

J Exp Med. 2016 Aug 22;213(9):1881-900. doi: 10.1084/jem.20151563. Epub 2016 Aug 15.

36.

Therapeutic targeting of CD70 and CD27.

Wajant H.

Expert Opin Ther Targets. 2016 Aug;20(8):959-73. doi: 10.1517/14728222.2016.1158812. Epub 2016 Mar 15. Review.

PMID:
26914723
37.

Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Lang I, Füllsack S, Wyzgol A, Fick A, Trebing J, Arana JA, Schäfer V, Weisenberger D, Wajant H.

J Biol Chem. 2016 Mar 4;291(10):5022-37. doi: 10.1074/jbc.M115.683946. Epub 2015 Dec 31.

38.

Soluble TL1A is sufficient for activation of death receptor 3.

Bittner S, Knoll G, Füllsack S, Kurz M, Wajant H, Ehrenschwender M.

FEBS J. 2016 Jan;283(2):323-36. doi: 10.1111/febs.13576. Epub 2015 Nov 24.

39.

Principles of antibody-mediated TNF receptor activation.

Wajant H.

Cell Death Differ. 2015 Nov;22(11):1727-41. doi: 10.1038/cdd.2015.109. Epub 2015 Aug 21. Review.

40.

Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.

Chopra M, Brandl A, Siegmund D, Mottok A, Schäfer V, Biehl M, Kraus S, Bäuerlein CA, Ritz M, Mattenheimer K, Schwinn S, Seher A, Grabinger T, Einsele H, Rosenwald A, Brunner T, Beilhack A, Wajant H.

Blood. 2015 Jul 23;126(4):437-44. doi: 10.1182/blood-2015-01-620583. Epub 2015 May 26.

41.

XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.

Ehrenschwender M, Bittner S, Seibold K, Wajant H.

Cell Death Dis. 2014 Dec 11;5:e1570. doi: 10.1038/cddis.2014.534.

42.

MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis.

El-Mesery M, Seher A, Stühmer T, Siegmund D, Wajant H.

Br J Pharmacol. 2015 Mar;172(5):1222-36. doi: 10.1111/bph.12998. Epub 2015 Jan 13.

43.

TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis.

Karl I, Jossberger-Werner M, Schmidt N, Horn S, Goebeler M, Leverkus M, Wajant H, Giner T.

Cell Death Dis. 2014 Oct 9;5:e1444. doi: 10.1038/cddis.2014.404. Erratum in: Cell Death Dis. 2014;5:e1556.

44.

Principles and mechanisms of CD95 activation.

Wajant H.

Biol Chem. 2014 Dec;395(12):1401-16. doi: 10.1515/hsz-2014-0212. Review.

PMID:
25153377
45.

Activated CD8+ T cells induce expansion of Vβ5+ regulatory T cells via TNFR2 signaling.

Joedicke JJ, Myers L, Carmody AB, Messer RJ, Wajant H, Lang KS, Lang PA, Mak TW, Hasenkrug KJ, Dittmer U.

J Immunol. 2014 Sep 15;193(6):2952-60. doi: 10.4049/jimmunol.1400649. Epub 2014 Aug 6.

46.

Analyzing the signaling capabilities of soluble and membrane TWEAK.

Trebing J, Arana JA, Salzmann S, Wajant H.

Methods Mol Biol. 2014;1155:31-45. doi: 10.1007/978-1-4939-0669-7_4.

PMID:
24788171
47.

Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.

Brunekreeft KL, Strohm C, Gooden MJ, Rybczynska AA, Nijman HW, Grigoleit GU, Helfrich W, Bremer E, Siegmund D, Wajant H, de Bruyn M.

Mol Cancer. 2014 Apr 17;13:85. doi: 10.1186/1476-4598-13-85.

48.

TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.

Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H.

Front Immunol. 2014 Feb 18;5:63. doi: 10.3389/fimmu.2014.00063. eCollection 2014.

49.

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.

Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, Thibault A, De Haard HJ.

MAbs. 2014 Mar-Apr;6(2):523-32. doi: 10.4161/mabs.27398. Epub 2013 Dec 6.

50.

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.

Trebing J, El-Mesery M, Schäfer V, Weisenberger D, Siegmund D, Silence K, Wajant H.

Cell Death Dis. 2014 Jan 30;5:e1035. doi: 10.1038/cddis.2013.555.

Supplemental Content

Loading ...
Support Center